Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2025 09:00 ET | Source: Alumis Inc.

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025
August 13, 2024 16:05 ET | Source: Alumis Inc.

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO...
July 29, 2024 08:00 ET | Source: Alumis Inc.

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program for ESK-001 for the treatment of psoriasis.
February 23, 2023 01:30 ET | Source: ONWARD Medical

ONWARD erhält weitere FDA Breakthrough Device Designations für Blasenkontrolle, Linderung von Spastiken und Blutdruckregulation nach Rückenmarksverletzung

EINDHOVEN, Niederlande, LAUSANNE, Schweiz und BOSTON, MA USA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Das Medizintechnikunternehmen ONWARD Medical N.V. (Euronext: ONWD), das innovative Therapien zur...
February 23, 2023 01:30 ET | Source: ONWARD Medical

ONWARD reçoit de nouvelles désignations de dispositifs révolutionnaires de la FDA pour le contrôle de la vessie, le soulagement de la spasticité et la régulation de la pression artérielle après une lésion de la moelle épinière

EINDHOVEN, Pays-Bas, LAUSANNE, Suisse, et BOSTON, MA, Etats-Unis, 23 févr. 2023 (GLOBE NEWSWIRE) -- ONWARD Medical SA (Euronext : ONWD), société de technologie médicale créant des thérapies...
February 23, 2023 01:30 ET | Source: ONWARD Medical

ONWARD ontvangt nieuwe FDA Breakthrough Device Designations voor blaascontrole, vermindering van spasticiteit en bloeddrukregeling bij dwarslaesiepatiënten

EINDHOVEN, Nederland, LAUSANNE, Zwitserland & BOSTON, MA, VS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), ONWARD Medical N.V. (Euronext: ONWD), het medische...
February 23, 2023 01:30 ET | Source: ONWARD Medical

ONWARD Receives New FDA Breakthrough Device Designations for Bladder Control, Alleviation of Spasticity, and Blood Pressure Regulation after Spinal Cord Injury

EINDHOVEN, the Netherlands, LAUSANNE, Switzerland, and BOSTON, MA USA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative...